Skip to main content Skip to section navigation Skip to footer
Capricor Therapeutics, Inc.
  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisors (DMD)
  • Our Science
    • CAP-1002 (Cell Therapy)
    • Exosomes Technology
    • Publications
    • Strategic Partnerships
  • Pipeline
    • Pipeline
    • Duchenne Muscular Dystrophy Overview
    • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In the News
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Leadership
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Latest Proxy Statement and Annual Report
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Overview
  • Press Releases
  • In the News
  • IR Calendar
  • Presentations
  • Email Alerts
Jun 17, 2022 9:00 am EDT

Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference

May 25, 2022 9:00 am EDT

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

May 18, 2022 9:00 am EDT

Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 10, 2022 4:01 pm EDT

Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 03, 2022 8:30 am EDT

Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10

Mar 29, 2022 9:00 am EDT

Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit

Mar 28, 2022 8:30 am EDT

Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 Patients

Mar 11, 2022 8:00 am EST

The Lancet Publishes Positive Results from Capricor Therapeutics’ Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy

Mar 10, 2022 4:01 pm EST

Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 03, 2022 9:15 am EST

Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • …Page 25
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
  • Visit us on Linkedin
  • Visit us on Facebook
  • Visit us on Instagram
  • Visit us on Twitter
©2023 Capricor Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Manage Cookie Preferences